Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984148 | 0.79 | DAO (0.52) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL25799818 | 0.76 | DAO (0.43) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL19325274 | 0.76 | DAO (0.43) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL24879524 | 0.76 | DAO (0.48) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL908781 | 0.75 | KDM4E (0.47) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL20204799 | 0.73 | DAO (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL18800357 | 0.73 | DAO (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL25054107 | 0.73 | DAO (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL25023927 | 0.72 | MCL1 (0.48) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL23564693 | 0.72 | DAO (0.39) | DAOAURKAAURKBINCENPMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-116648244-B | Terpyridyl dione compound or salt thereof, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116648244-A | Terpyridyl dione compound or salt thereof, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4219463-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | TNF, MAPKAPK2, MAPK1 | DAO 2280/4885AURKA 2984/4885AURKB 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.